Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dicks Sporting Goods Inc (DKS) vs Cassava Sciences Inc (FLNA) Price & Performance

Dicks Sporting Goods IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Dicks Sporting Goods Inc vs Cassava Sciences Inc — how do they compare? Dicks Sporting Goods Inc trades at $211.39 (market cap $18.92B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Dicks Sporting Goods Inc is far larger — about 359.3× Cassava Sciences Inc's market cap, and Dicks Sporting Goods Inc pays a 2.37% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

DKSFLNA
Market Cap
$18.92B$52.66M
Sector
Consumer CyclicalHealth
52-Week High
$239.17$4.64
52-Week Low
$187.78$1.09
Enterprise Value
$25.71B-$33.92M
Dividend Yield
2.37%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dicks Sporting Goods Inc

Dick's Sporting Goods (DKS) trades at $216.10, down 0.86% with a bearish technical outlook despite strong fundamentals. The company reported consistent earnings beats, with Q1 2026 EPS of $2.90 exceeding expectations, and maintains solid profitability with a 4.71% net margin. Recent developments include the launch of ScoreCard+ loyalty program and Lids partnership expansion. Analyst consensus remains strongly bullish with a $261 price target, though legal scrutiny over fiduciary duties presents near-term headwinds.

DKS offers attractive valuation with a P/E of 20.58 and P/S of 0.96, trading below analyst targets. Growth catalysts include market share gains and strategic partnerships, but risks involve competitive pressures and potential legal overhangs. The stock's current dip may present a buying opportunity for long-term investors given fundamental strength and institutional support.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dicks Sporting Goods Inc

Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.

Read more on DKS

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA